article thumbnail

Combination of Metabolomics and Bioinformatics to Reveal the Mechanism of Luteolin in the Treatment of Cervical Cancer

Chemical Biology and Drug Design

The remarkable therapeutic potential of luteolin against cervical cancer can be ascribed to its profound influence on amino acid and nucleotide metabolism, substantiated by the seamless integration of metabolomics, bioinformatics, and molecular docking techniques in this comprehensive investigation.

article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Transforming cancer treatment for greatest impact

Drug Target Review

Could you provide insights into the driving factors behind exploring novel treatments for cancer types? Could you provide further details on how this phenomenon could impact broader treatment outcomes? What aspects prompted this research direction? The concept of the ‘abscopal effect’ in the 4T1 tumour model is intriguing.

Treatment 105
article thumbnail

ANKRD22 promotes M2 polarization in lung adenocarcinoma macrophages via the glycolytic pathway

Chemical Biology and Drug Design

The expression of ANKRD22 in LUAD and its enriched pathway were analyzed by bioinformatics analysis. Bioinformatics analysis, qRT-PCR, and western blot showed that ANKRD22 was highly expressed in LUAD, which had a positive connection with M2 marker genes. Mitochondrial membrane potential was assessed using the JC-1 probe.

article thumbnail

Brusatol induces ferroptosis to inhibit hepatocellular carcinoma progression by targeting ATF3

Chemical Biology and Drug Design

Therefore, our research revealed the biological effect of brusatol treatment and provided ATF3 as a novel therapeutic target and prognostic biomarker for HCC therapy. However, the exact mechanism of BRU in the treatment of hepatocellular carcinoma (HCC) remains unknown.

RNA 100
article thumbnail

Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression

Chemical Biology and Drug Design

Bioinformatics analysis was performed to predict the molecular targets of COP. This study showed that COP treatment markedly suppressed the malignant biological behaviors of bladder carcinoma cells. COP treatment modulated the expression level of cyclin D1 and CYP450 via XPO1.

article thumbnail

The first major set of genetic associations found in long COVID

Drug Target Review

The article mentions that TLR4 antagonists have been identified as potential candidates for repurposing long COVID treatment. Type 2 diabetes-related signalling pathways and insulin resistance were also a key theme within the genes associated with long COVID. Can you elaborate on how these antagonists may help with long COVID?